Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Braz. j. med. biol. res ; 51(3): e6426, 2018. tab, graf
Article in English | LILACS | ID: biblio-889045

ABSTRACT

Occupational noise-induced hearing loss (ONIHL) is a prevalent occupational disorder that impairs auditory function in workers exposed to prolonged noise. However, serum microRNA expression in ONIHL subjects has not yet been studied. We aimed to compare the serum microRNA expression profiles in male workers of ONIHL subjects and controls. MicroRNA microarray analysis revealed that four serum microRNAs were differentially expressed between controls (n=3) and ONIHL subjects (n=3). Among these microRNAs, three were upregulated (hsa-miR-3162-5p, hsa-miR-4484, hsa-miR-1229-5p) and one was downregulated (hsa-miR-4652-3p) in the ONIHL group (fold change >1.5 and Pbon value <0.05). Real time quantitative PCR was conducted for validation of the microRNA expression. Significantly increased serum levels of miR-1229-5p were found in ONIHL subjects compared to controls (n=10 for each group; P<0.05). A total of 659 (27.0%) genes were predicted as the target genes of miR-1229-5p. These genes were involved in various pathways, such as mitogen-activated protein kinase (MAPK) signaling pathway. Overexpression of miR-1229-5p dramatically inhibited the luciferase activity of 3′ UTR segment of MAPK1 (P<0.01). Compared to the negative control, HEK293T cells expressing miR-1229-5p mimics showed a significant decline in mRNA levels of MAPK1 (P<0.05). This preliminary study indicated that serum miR-1229-5p was significantly elevated in ONIHL subjects. Increased miR-1229-5p may participate in the pathogenesis of ONIHL through repressing MAPK1 signaling.


Subject(s)
Humans , Male , Adult , Middle Aged , Occupational Exposure/adverse effects , Mitogen-Activated Protein Kinase 1/analysis , MicroRNAs/blood , Hearing Loss, Noise-Induced/blood , Occupational Diseases/blood , Biomarkers/blood , Case-Control Studies , Gene Expression Regulation , MicroRNAs/genetics , Real-Time Polymerase Chain Reaction , Gene Ontology , Hearing Loss, Noise-Induced/genetics , Occupational Diseases/genetics
2.
Braz. j. med. biol. res ; 47(8): 646-654, 08/2014. tab, graf
Article in English | LILACS | ID: lil-716273

ABSTRACT

The physiological mechanisms involved in isoproterenol (ISO)-induced chronic heart failure (CHF) are not fully understood. In this study, we investigated local changes in cardiac aldosterone and its synthase in rats with ISO-induced CHF, and evaluated the effects of treatment with recombinant human brain natriuretic peptide (rhBNP). Sprague-Dawley rats were divided into 4 different groups. Fifty rats received subcutaneous ISO injections to induce CHF and the control group (n=10) received equal volumes of saline. After establishing the rat model, 9 CHF rats received no further treatment, rats in the low-dose group (n=8) received 22.5 μg/kg rhBNP and those in the high-dose group (n=8) received 45 μg/kg rhBNP daily for 1 month. Cardiac function was assessed by echocardiographic and hemodynamic analysis. Collagen volume fraction (CVF) was determined. Plasma and myocardial aldosterone concentrations were determined using radioimmunoassay. Myocardial aldosterone synthase (CYP11B2) was detected by quantitative real-time PCR. Cardiac function was significantly lower in the CHF group than in the control group (P<0.01), whereas CVF, plasma and myocardial aldosterone, and CYP11B2 transcription were significantly higher than in the control group (P<0.05). Low and high doses of rhBNP significantly improved hemodynamics (P<0.01) and cardiac function (P<0.05) and reduced CVF, plasma and myocardial aldosterone, and CYP11B2 transcription (P<0.05). There were no significant differences between the rhBNP dose groups (P>0.05). Elevated cardiac aldosterone and upregulation of aldosterone synthase expression were detected in rats with ISO-induced CHF. Administration of rhBNP improved hemodynamics and ventricular remodeling and reduced myocardial fibrosis, possibly by downregulating CYP11B2 transcription and reducing myocardial aldosterone synthesis.


Subject(s)
Animals , Humans , Male , Aldosterone/blood , /metabolism , Heart Failure/drug therapy , Myocardium/metabolism , Natriuretic Agents/therapeutic use , Natriuretic Peptide, Brain/therapeutic use , Aldosterone/genetics , Cardiotonic Agents , Chronic Disease , Collagen/analysis , Disease Models, Animal , Echocardiography , Fibrosis/etiology , Heart Failure/chemically induced , Heart Failure/metabolism , Hemodynamics/drug effects , Isoproterenol , Long-Term Care , Myocardium/pathology , Natriuretic Agents/administration & dosage , Natriuretic Peptide, Brain/administration & dosage , Rats, Sprague-Dawley , Real-Time Polymerase Chain Reaction , Recombinant Proteins/therapeutic use , Transcription, Genetic/drug effects , Ventricular Remodeling/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL